Revvity, Inc. (RVTY) Presents At Baird 2025 Global Healthcare Conference (Transcript)

Revvity (NYSE:RVTY) reported Q2 results slightly ahead of expectations, driven by low single-digit growth in Life Science consumables and robust high-teens growth in its Software segment, which is set to launch a significant large molecule workflow product. Conversely, instrument sales continued their mid-to-high single-digit decline due to market uncertainties, and the Diagnostics segment faces new pressures in China from a policy change impacting multiplex tests, leading to an anticipated 25% decline in that ~6% revenue segment for H2. Despite these challenges, Revvity maintains its 2026 operating margin target of 28% through structural actions and continues significant share repurchases, highlighting confidence in its long-term prospects, particularly in high-growth areas like Software and specialty consumables.

Analysis

Revvity's second-quarter performance was slightly ahead of internal expectations, but reveals a significant divergence across its business segments. The Software division, representing 9% of total revenue, is a standout performer, with growth guided to high teens for the year, well above its 9-11% long-range plan (LRP). This strength is underpinned by a major upcoming product launch for large molecule workflows, which is positioned as a historically significant expansion of its addressable market. In contrast, the core Life Sciences segment shows a mixed picture: consumables are demonstrating resilience with a fifth consecutive quarter of low single-digit growth, indicating stable underlying lab activity. However, instrument sales continue to be a considerable drag, declining mid-to-high single digits as customers maintain a cautious, wait-and-see approach. The Diagnostics segment, roughly half of the company, is facing an acute and unexpected headwind in China due to a new government policy discouraging multiplex testing. This is projected to cause a 25% decline in the back half of the year for the affected immunodiagnostics business, which accounts for approximately 6% of total company revenue. Despite these pressures, management is reaffirming its commitment to a 28% operating margin baseline for 2026, driven by structural cost actions. This confidence is further demonstrated by an aggressive capital return policy, having repurchased nearly 9% of the company's stock over the past year.

Key Decisions for Investors

• Investors should closely monitor the bifurcation in Revvity's portfolio, weighing the high-teen growth and strategic product pipeline in the Software segment against the persistent cyclical weakness in instruments and the new, material policy-driven headwinds in China's diagnostics market.
• The upcoming large molecule workflow software launch is a key catalyst; its successful rollout and adoption could sustain the segment's premium growth and validate management's strategic focus on this high-margin business.
• The 25% projected H2 decline in the China immunodiagnostics business should be factored into near-term models, with the headwind expected to persist until it is anniversaried in mid-2026, representing a key risk to monitor.
• Management's ability to deliver on its 28% operating margin target for 2026 despite top-line challenges is a critical test of execution, while the substantial share buyback program provides valuation support and signals strong internal conviction in the long-term outlook.